Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma, Inc. (TRAW)
Company Research
Source: GlobeNewswire
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of Phase 2 dose Preclinical data showed potent inhibition of drug-resistant and bird influenza viruses Phase 2 study expected to begin in H1 2025 Improved therapy is an important need for both seasonal and pandemic flu NEWTOWN, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir). Tivoxavir was designed as a potential best-in-class inhi
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswire
- Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza TreatmentPR Newswire
- Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro InhibitorGlobeNewswire
- Traws Pharma, Inc. Appoints Luba Greenwood to Board of DirectorsGlobeNewswire
TRAW
Earnings
- 11/14/24 - Miss
TRAW
Sec Filings
- 11/15/24 - Form S-8
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- TRAW's page on the SEC website